Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Luwei Pharmaceutical Group is a Chinese pharmaceutical and specialty ingredients manufacturer focused primarily on vitamin C active pharmaceutical ingredient and related ascorbate derivatives. The company operates an integrated production chain in Zibo, Shandong, covering upstream materials such as glucose and sorbitol as well as downstream vitamin C derivatives, and it markets products into pharmaceutical, food, feed, and nutraceutical end markets. Luwei appears to be a large-scale commercial manufacturer rather than a clinical-stage drug developer, with GMP and ISO-certified operations and significant export activity to North America, Europe, Japan, and other markets. Public sources describe it as one of the major vitamin C producers in China, with multiple factories, in-house utilities such as power and wastewater treatment, and a provincial engineering technology research center. The business is best understood as a commercial API and health-ingredient supplier rather than an innovation-driven biotech pipeline company.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Luwei Pharmaceutical Group.